louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06056622: Motion Sickness Rehabilitation for Virtual Reality
Official title: Overcoming Motion Sickness in Immersive Virtual Reality
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Motion Sickness
Keywords: Rehabilitation
Balance
Reflex
Lead sponsor: Abant Izzet Baysal University
Sponsor class: OTHER
First posted: 2023-09-28
Enrollment: 121
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Two groups with a sham control. Assessments will be performed before intervention, and four months after the last session.
Primary purpose: TREATMENT

Brief summary: The objective of this study was to investigate the effect of a rehabilitation program on motion sickness. A combined rehabilitation program will be given participants who showed motion sickness symptoms.

Detailed description: In the realm of virtual environments and simulators, a significant hurdle that hampers user engagement resides in the manifestation of adverse effects. These deleterious consequences become apparent during prolonged exposure to virtual settings, with approximately 30% of users grappling with symptoms like nausea and up to 40% reporting eyestrain. Furthermore, users frequently describe a constellation of other discomforting sensations, including headaches, dizziness or vertigo, compromised postural stability, drowsiness, increased salivation, and perspiration. These adverse effects have been documented in scientific literature under various monikers, with 'cybersickness' and 'motion sickness' (MS) being the most prevalent designations.

Motion sickness, a vexing symptom characterized by discomfort experienced during movements unrelated to one's bodily motions, such as those encountered during travel by air, sea, or land, lies at the crux of this issue. The pathophysiological elucidation of the mechanisms underlying MS centers around the notion of sensory conflict or sensory mismatch. This conflict arises from disparities between the sensory information derived from kinaesthetic inputs, the vestibular and visual systems, and the sensory patterns engendered by the virtual environment

Eligibility criteria: Inclusion Criteria:

* having stereoacuity score of 3552 arc/s on the Titmus Fly Test

Exclusion Criteria:

* having partial or total vision loss
* being diagnosed with vertigo
* having previous experience of head mounted virtual reality devices

Primary outcomes:
measure: Virtual Reality Symptoms Questionnaire
timeFrame: four weeks
Secondary outcomes:
measure: Visual Analog Scale
timeFrame: four weeks
measure: Biodex System Analysis
timeFrame: four weeks
measure: Flaming Balance Test
timeFrame: four weeks
Other outcomes:
Locations:
city: Bolu
country: Turkey
facility: Abant Izzet Baysal University
state: Merkez
Study officials:
affiliation: Abant Izzet Baysal University
name: Ramazan KURUL, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01190722: A Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain
Official title: A Randomized Study Comparing Etoricoxib and Diclofenac Sodium in Post Hallux Valgus Surgery Pain
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Hallux Valgus
Postoperative Pain
Keywords: Day case surgery
postoperative pain
NSAIDs
Coxibs
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2010-08-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators hypothesize that cyclooxygenas-II-selective inhibitors (Coxibs) provide a better patients assessed overall satisfaction when used for pain management after elective hallux valgus surgery as compared to traditional Non-steroidal anti-inflammatory drugs (NSAIDs).

Detailed description: The aim of the present study is to compare patients' satisfaction with pain medication during the first 7 first postoperative days following elective hallux valgus surgery in general anaesthesia between etoricoxib and diclofenac in a prospective randomised double-blind study design.

Eligibility criteria: Inclusion Criteria:

* American Society of Anesthesiology (ASA) physiological class 1-2 patients
* aged 18-65 years
* scheduled for elective hallux valgus surgery in general anesthesia

Exclusion Criteria:

* NSAID allergy
* liver disease
* renal disease
* uncontrolled cardiovascular disease
* Lithium therapy
* chronic pain
* regular analgesia use

Primary outcomes:
measure: Patients Global Evaluation of Study Medication
timeFrame: postoperative day 1-6
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Karolinska Institutet
name: Jan Jakobsson, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04578522: Correlation Between the Severity of Coronary Artery Disease and Peripheral Arterial Stiffness in Patients With Premature Coronary Heart Disease
Official title: Correlation Between the Severity of Coronary Artery Disease and Peripheral Arterial Stiffness in Patients With Premature Coronary Heart Disease
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Premature Coronary Heart Disease
Keywords: Premature coronary heart disease
Degree of coronary stenosis
arterial stiffness
Lead sponsor: Chongqing Medical University
Sponsor class: OTHER
First posted: 2020-10-08
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with primary coronary heart disease were male \< 55 years old and female \< 65 years old

Brief summary: Premature coronary heart disease (CHD) refers to the onset of myocardial infarction in men \< 55 years old, women \< 65 years old. At present, researches on early-onset coronary heart disease mostly focus on its risk factors and clinical characteristics, but there is no relevant research on the relationship between early-onset myocardial infarction and atherosclerosis.

Detailed description: Premature coronary heart disease is defined as the first onset of male \< 55 years old, female \< 65 years old, confirmed by clinical examination. A number of studies have found that smokers have a significantly increased risk of acute myocardial infarction, and suggest that continued smoking is still an independent predictor of mace. These findings suggest that smoking is significantly associated with early-onset coronary heart disease. A number of studies have found that smoking can increase peripheral arterial stiffness. At present, there is no study on peripheral arterial stiffness in patients with early-onset myocardial infarction, so we suspect that peripheral arterial stiffness in patients with early-onset myocardial infarction is significantly increased

Eligibility criteria: Inclusion Criteria:

* The onset of coronary heart disease (including acute coronary syndrome and stable angina pectoris) was less than 55 years old in men and 65 years in women

Exclusion Criteria:

* Non coronary heart disease leading to chest pain (myocarditis, pericarditis, pulmonary embolism, aortic dissection, unstable angina pectoris) definite infection tumor liver and kidney insufficiency autoimmune disease acromegaly hyperthyroidism and subclinical hyperthyroidism secondary hypertension, etc.

Primary outcomes:
measure: Arterial stiffness
timeFrame: On admission
measure: Degree of coronary stenosis
timeFrame: On admission
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: The First Affiliated Hospital of Chongqing Medical University
Study officials:
affiliation: First Affiliated Hospital of Chongqing Medical University
name: Dongying Zhang, doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT01274039: Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide
Official title: Comparing Eye Pressure Using Maximal Tolerated Local Therapy or Systemic Acetazolamide. A Possible Pretreatment for Trabeculectomy Surgery.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Control of Elevated Eye Pressure by Local and Systemic Therapy
Lead sponsor: University of Cologne
Sponsor class: OTHER
First posted: 2011-01-11
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients of the university hospital with a planed trabeculectomy in 3 to 4 weeks.

Brief summary: Local therapy for glaucoma is known to induce a conjunctival inflammation. Because of this, trabeculectomy is more likely to fail. The investigators exchange the local therapy by systemic therapy using acetazolamide and measure the eye pressure using local therapy and systemic therapy using acetazolamide. The investigators suspect an elevated eye pressure using acetazolamide compared to local therapy. In summary acetazolamide could be a better choice in reference to conjunctival inflammation, but a worse choice in reference to controlling eye pressure.


Eligibility criteria: Inclusion Criteria:

* Patients with uncontrolled intraocular eye pressure
* Patients with planed trabeculectomy in 3 to 4 weeks

Exclusion Criteria:

* Patients not meeting the inclusion criteria
* Patients with known intolerance to acetazolamide

Primary outcomes:
measure: Eye pressure
timeFrame: Once at the beginning of the study and once 3 to 4 weeks later
Secondary outcomes:
Other outcomes:
Locations:
city: Cologne
country: Germany
facility: University of Cologne
Study officials:
References:
Clinical trial NCT04530539: The Effect of Melatonin and Vitamin C on COVID-19
Official title: The Effect of Melatonin and Vitamin C on COVID-19
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Covid19
SARS-CoV Infection
Keywords: vitamin c
melatonin
Lead sponsor: Lancaster General Hospital
Sponsor class: OTHER
First posted: 2020-08-28
Enrollment: 122
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.


Eligibility criteria: Inclusion Criteria

* COVID-19 positive test (outpatient testing),
* Age \>50 (chosen based greater risk for older patients to be vitamin deficient, age \>65 not used so as not to be too restrictive in the inclusion criteria)
* Experiencing symptoms for \<5 days prior to enrollment
* Able to read and write in English or Spanish
* Able to access REDCap daily
* Valid email address
* Current has a Lancaster General Health primary care physician

Exclusion Criteria

* COVID-19 test ordered pre-procedure for asymptomatic screening
* Currently taking vitamin C supplements
* Currently taking melatonin supplements
* Currently hospitalized
* Deceased
* Currently pregnant
* Currently incarcerated

Primary outcomes:
measure: Symptom Severity
timeFrame: 14 days
Secondary outcomes:
measure: Symptom progression
timeFrame: 14 days
Other outcomes:
Locations:
city: Lancaster
country: United States
facility: Lancaster General Health
state: Pennsylvania
Study officials:
affiliation: Penn Medicine Lancaster General Health
name: Corey Fogleman
role: PRINCIPAL_INVESTIGATOR
affiliation: Physician
name: Corey Fogleman, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06481839: Impact of Starting Dose of Vasopressor on Hemodynamic Response in Shock
Official title: Impact of Starting Dose of Vasopressor on Hemodynamic Response in Shock
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Shock
Lead sponsor: University of Illinois at Chicago
Sponsor class: OTHER
First posted: 2024-07-01
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This study is designed to assess the effect of initial vasopressor dose on clinical outcomes. To date, there are no clinical guidelines or recommendations regarding the dose of vasopressor medication that should be initiated before titrating to a mean arterial pressure (MAP) in patients with circulatory shock. High heterogeneity and clinical equipoise regarding this variable exist in routine clinical practice. However, there is strong evidence that delays in achieving MAP goals lead to worse clinical outcomes. The study will randomize patients with circulatory shock to a low (5mcg/min of norepinephrine) or high (15mcg/min of norepinephrine) initial starting dose followed by the usual protocolized titration to MAP goal. The time to reach the goal MAP, organ dysfunction, hospital length of stay, and mortality will be measured for each group.


Eligibility criteria: Inclusion Criteria:

* Patients at least 18 years old
* Patients who are diagnosed with shock (MAP \< 65 mmHg) require the initiation of vasopressors
* Care provided in the ED or admission to the Medical Intensive Care Unit (MICU)
* Norepinephrine chosen as first-line vasopressor by the treating clinician

Exclusion Criteria:

* Patients who are receiving vasopressors or inotropes prior to UI Health hospital presentation/admission
* Baseline MAP \>/= 65 mmHg
* Pregnant patients (checked as standard of care on admission)
* Prisoners.
* Immediate post-cardiac arrest patients

Primary outcomes:
measure: Mean arterial blood pressure
timeFrame: During first shock episode, up to 28 days of shock episode.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04098939: Replaceability of Fluoroscopy and Ultrasound in the Evaluation of Hemidiaphragm Excursion
Official title: Replaceability of Fluoroscopy and Ultrasound in the Evaluation of Hemidiaphragm Excursion"
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diaphragm Disease
Lead sponsor: University of Aarhus
Sponsor class: OTHER
First posted: 2019-09-23
Enrollment: 42
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy participants. Participants with prior COVID-19 infection. Participants with lung diseases. Participants with heart diseases.

Brief summary: Precise measurement of diaphragm function is difficult. Several methods exist. No are sufficiently validated.

With this study, the investigators wish to investigate the validity of different ultrasound and radiological methods and compare them with inspiratory pressure measurements.

Detailed description: Fluoroscopy assessment of diaphragm motility is obtained and simultaneously correlated to sonographic assessments of motility.

Eligibility criteria: Inclusion Criteria:

* Completed informed consent
* one of the following conditions:

  * Healthy participants, control group
  * Lung disease group.

    * COPD or
    * Ideopatic pulmonary fibrosis.
  * Heart disease group.

Heart disease that lead to:

* heart transplantat or
* left ventricular assist device.

Exclusion Criteria:

* Known diaphragm dysfunction.
* Neuromuscular disease.
* Pleural effusion.
* Pneumothorax.
* In the healthy group: Significant comorbidity that affect heart og lung function (arterial hypertention, mild valve disease and COPD without symptoms are accepted).
* In the healthy group and in the lung disease group: Previous thorax surgery.

Primary outcomes:
measure: Diaphragm Function
timeFrame: during intervention, up to 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Søren Helbo Skaarup
Study officials:
affiliation: Aarhus University Hospital
name: Søren H Skaarup
role: STUDY_CHAIR
affiliation: Aarhus University Hospital
name: Peter Juhl-Olsen
role: STUDY_CHAIR
affiliation: Aarhus University Hospital
name: Brian Løgstrup
role: STUDY_CHAIR
affiliation: Aarhus University Hospital
name: Thomas Birkelund
role: STUDY_CHAIR
affiliation: Aarhus University Hospital
name: Morten Bendixen
role: STUDY_CHAIR
References:
Clinical trial NCT05634239: Senior Health Clinic Study
Official title: Senior Health Clinic for 75-year-old Home-dwelling Finns
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cardiovascular Diseases
Dementia
Frailty
Keywords: Health Clinic
Prevention
Home-dwelling
Older people
Functional ability
Lead sponsor: University of Turku
Sponsor class: OTHER
First posted: 2022-12-02
Enrollment: 2500
Sex: ALL
Minimum age (years): 75
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Turku Senior Health Clinic study The Turku Senior Health Clinic Study was targeted to 75-year-old citizens with an underlying idea that at that age it would be almost the last moment to nudge people towards healthy lifestyle and taking care of their health and functional ability to maintain independent living.

The short-term aims of the Turku Senior Health Clinic Study are to survey health and functional statuses and prevalence of specified risk factors for CVDs, dementia, frailty, and functional decline of 75-year-old independently home-dwelling citizens of the city of Turku. The aims also include assessment the frequency of follow-up treatments needed, and recommendations given for lifestyle changes and evidence-based drug treatment, as well as fulfillment of these recommendations. Also, participants feedback on the Turku Senior Health Clinic will be assessed. In addition, based on the results, recommendation for the content and implementation of preventive health clinic targeted to older people will be provided. The long-term aim of the research project is to assess the effects of the Turku Senior Health Clinic on the need of institutional care and home care as well as the cost-effectiveness of the clinic during the 10-year follow-up. For this purpose, participants of the Senior Health Clinic Study will be compared to that of non-participants and earlier cohorts of 75-year-olds in terms of the use of home care and institutional care.


Eligibility criteria: Inclusion Criteria:

* citizens of Turku
* home-dwelling

Exclusion Criteria:

* use of munical home care

Primary outcomes:
measure: Use of home care and institutional care.
timeFrame: 10 year
Secondary outcomes:
Other outcomes:
Locations:
city: Turku
country: Finland
facility: University of Turku
state: University Of Turku
Study officials:
affiliation: University of Turku
name: Laura Viikari
role: STUDY_DIRECTOR
References:
Clinical trial NCT05031039: Skeletal and Dental Maturational Stages in a Sample of Egyptian Subjects With Cleft Lip and Palate Deformity
Official title: Skeletal and Dental Maturational Stages in a Sample of Egyptian Subjects With Cleft Lip and Palate Deformity: A Cross-Sectional Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cleft Lip and Palate
Keywords: skeletal & dental maturational stages
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2021-09-01
Enrollment: 250
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Egyptian subjects with Cleft Lip and Palate Deformity

Brief summary: The aim of this research is to evaluate the skeletal and dental maturation of cleft lip and palate patients in a sample of Egyptian population using the CVM as indicator for the skeletal maturation and the Demirjian method as indicator for the dental one when compared to a group of Egyptian non-CLP subjects of the same age.

Detailed description: Chronological age (CA) is not considered an accurate method for assessing the stage of physical or growth development of an individual in childhood or adolescence. For that reason, skeletal and dental maturation can be used in order to examine the rate of physical maturation of the population. Cervical vertebral maturation (CVM) method uses lateral cephalometric radiography to evaluate skeletal maturity. It is considered the preferable method due to its advantage of avoiding unnecessary extra radiation. The CVM method developed by Baccetti et al. (2005) depends on the morphology of the three cervical vertebrae (C2, C3, and C4), which divided skeletal growth into six stages of based on the morphology of the previously mentioned cervical vertebrae. The Demirjian method is considered as one of the most worldwide used method for assessment of the dental maturation due to its reliability. It depends on panoramic x-rays through which the dental developmental stage of 7 lower left teeth appears, and according to the gender of the patient the sum of values of the teeth will be transform to age through the standard tables of Carmen M. Nolla; 1960.

Eligibility criteria: Inclusion Criteria:

(1) Subjects with non-syndromic CLP aged 6-18 years. (2) Subjects with no CLP deformity, aged 6-18 years. (4) Patients having complete records comprising dental/medical history and a lateral cephalometric and panoramic radiograph.

(5) No congenitally missing teeth in the mandible. (6) No previous history of trauma to the face, neck.

Exclusion Criteria:

* Radiographs of poor quality.
* Any growth or hereditary or systematic diseases or syndromes
* Any trauma or fracture of the jaw that might have affected the normal growth of permanent dentition.

Primary outcomes:
measure: dental age
timeFrame: 5 months
Secondary outcomes:
measure: skeletal age
timeFrame: 5 months
Other outcomes:
Locations:
Study officials:
References: